Discover open access scientific publications

Search, annotate, share and cite publications

Publications by A. Swalduz

P1.01-67 Clinical Relevance of ALK/ROS1 Resistance Mutations and Other Acquired Mutations Detected by Liquid Biopsy in Advanced NSCLC Patients

Journal of Thoracic Oncology

English

MA16.09 Feasibility, Clinical Relevance of ALK/ROS1 Fusion Variant Detection by Liquid Biopsy in Advanced Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

English

Related publications

Clinical Evaluation of the Utility of a Liquid Biopsy (Circulating Tumoral Cells and ctDNA) to Determine the Mutational Profile (EGFR, KRAS, ALK, ROS1 and BRAF) in Advanced NSCLC Patients

English

New Driver Mutations Detected in NSCLC

Cancer Discovery

Oncology

2016

English

OA02.02 Safety and Preliminary Clinical Activity of Ropotrectinib (TPX-0005), a ROS1/TRK/ALK Inhibitor, in Advanced ROS1 Fusion-Positive NSCLC

Journal of Thoracic Oncology

English

KRAS Mutations and Its Implications for Acquired Resistance to Treatment in NSCLC

Oncotarget

Oncology

2017

English

MA26.01 Accumulation of Concomitant Mutations Involved in Drug Resistance in the Sequential ALK TKI Treatments of ALK-Positive NSCLC

Journal of Thoracic Oncology

English

P1.01-30 Crizotinib in Advanced Non-Adenocarcinoma, NSCLC (NA-NSCLC) Patients With ALK Rearrangement: A Retrospective Study and Literature Review

Journal of Thoracic Oncology

English

P3.08-18 Changing Resistance Mechanisms in Rebiopsies of ALK-Positive NSCLC During Multiple Lines of Therapy: ALK/BRAF-Mutations Followed by EMT

Journal of Thoracic Oncology

English

P1.01-101 Survival Benefit of Sequential Therapy in ALK Positive Olioprogressive NSCLC Patients After Crizotinib Resistance

Journal of Thoracic Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by A. Swalduz

P1.01-67 Clinical Relevance of ALK/ROS1 Resistance Mutations and Other Acquired Mutations Detected by Liquid Biopsy in Advanced NSCLC Patients

MA16.09 Feasibility, Clinical Relevance of ALK/ROS1 Fusion Variant Detection by Liquid Biopsy in Advanced Non-Small Cell Lung Cancer

Related publications

Clinical Evaluation of the Utility of a Liquid Biopsy (Circulating Tumoral Cells and ctDNA) to Determine the Mutational Profile (EGFR, KRAS, ALK, ROS1 and BRAF) in Advanced NSCLC Patients

New Driver Mutations Detected in NSCLC

OA02.02 Safety and Preliminary Clinical Activity of Ropotrectinib (TPX-0005), a ROS1/TRK/ALK Inhibitor, in Advanced ROS1 Fusion-Positive NSCLC

KRAS Mutations and Its Implications for Acquired Resistance to Treatment in NSCLC

MA26.01 Accumulation of Concomitant Mutations Involved in Drug Resistance in the Sequential ALK TKI Treatments of ALK-Positive NSCLC

P1.01-30 Crizotinib in Advanced Non-Adenocarcinoma, NSCLC (NA-NSCLC) Patients With ALK Rearrangement: A Retrospective Study and Literature Review

P3.08-18 Changing Resistance Mechanisms in Rebiopsies of ALK-Positive NSCLC During Multiple Lines of Therapy: ALK/BRAF-Mutations Followed by EMT

P1.01-101 Survival Benefit of Sequential Therapy in ALK Positive Olioprogressive NSCLC Patients After Crizotinib Resistance